We have located links that may give you full text access.
CLINICAL TRIAL
ENGLISH ABSTRACT
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
[Evaluation of long-term efficacy on plasma-derived hepatitis B vaccine].
From April 1986 to May 1990, 265 pupils aged 5 to 9 years in Xian suburbs were studied to evaluate long-term efficacy of plasma-derived hepatitis B vaccine made in China. Anti-HBs titers in vaccine group reached the highest at twelfth month after the first injection and decreased afterwards. The positive rate of anti-HBs decreased slow, but geometric mean titers of anti-HBs fell sharply. Compared with placebo group, the differences were all significant. The peak anti-HBs titers and the response time positively correlated with the persistence of anti-HBs. 4 years observation showed that protection rate of hepatitis B vaccine against HBV infection was 80%. Protection rate was 100% if HBsAg was only considered.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app